Editas Medicine, INC

Editas Medicine, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including director elections, advisory vote on executive compensation, and ratification of its independent auditor.

Editas Medicine announced the pricing of an underwritten public offering of common stock and accompanying warrants, aiming to raise approximately $125 million.

Editas Medicine has suspended and terminated its at-the-market offering program with TD Cowen, ceasing further sales of common stock under the existing agreement.

Editas Medicine announced robust preclinical data for its EDIT-401 candidate, showing significant reductions in key cardiovascular risk factors in non-human primates.

Editas Medicine presented new preclinical data for its hyperlipidemia candidate, EDIT-401, showing significant LDL cholesterol reduction in non-human primates.

Editas Medicine announced first quarter 2026 financial results, highlighting progress in its EDIT-401 gene editing program for hyperlipidemia and providing updates on intellectual property and upcoming data presentations.

Editas Medicine reports reduced net loss and extended cash runway into Q3 2027 following a strategic shift to in vivo gene editing and significant restructuring.

Editas Medicine reports reduced net losses and extended cash runway into Q2 2027 following a strategic pivot to in vivo gene editing and significant restructuring.

Editas Medicine reports a net loss of $76.1 million for Q1 2025, shifting focus to in vivo gene editing and advancing preclinical programs.

Editas Medicine reported a net loss of $62.1 million for the third quarter of 2024, while highlighting progress in its clinical programs and strategic shifts towards in vivo gene editing.

Editas Medicine's Q2 2024 report highlights increased R&D spending, progress in clinical trials for reni-cel, and a net loss of $67.6 million.

Editas Medicine reported a net loss of $61.95 million for the first quarter of 2024, with increased research and development expenses and a decrease in collaboration revenue.

Editas Medicine's 10-K filing summarizes the company's financial performance for fiscal year 2024 and outlines its strategic priorities through 2027, focusing on in vivo gene editing and pipeline advancement.

Editas Medicine's 10-K filing details its capital structure, ongoing clinical trials for gene editing therapies, and strategic partnerships aimed at advancing its pipeline.

Linda Burkly, EVP, CHIEF SCIENTIFIC OFFICER of Editas Medicine, Inc., sold 4,928 shares of common stock on July 28, 2026 for $2.67 per share.

Editas Medicine CFO Amy Parison sold 464 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Editas Medicine CEO Gilmore O'Neill sold 15,380 shares of common stock to satisfy tax withholding requirements related to RSU vesting.

Linda Burkly, EVP and Chief Scientific Officer of Editas Medicine, sold 731 shares to cover tax obligations related to RSU vesting.

Editas Medicine's CEO, Gilmore Neil O'Neill, was granted 1,015,200 stock options with an exercise price of $2.54, vesting over four years.

Editas Medicine's SVP and Chief Financial Officer, Amy Parison, was granted 292,856 stock options with an exercise price of $2.54.

Editas Medicine, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Editas Medicine, Inc. has filed a definitive proxy statement with the SEC.

Editas Medicine is seeking stockholder approval for an amended stock incentive plan and an increase in authorized shares at its upcoming 2025 annual meeting.

Editas Medicine, Inc. has filed a definitive proxy statement with the SEC.

Editas Medicine will hold its 2024 Annual Meeting of Stockholders virtually on May 30, 2024, to vote on director elections, executive compensation, and auditor ratification.

RA Capital Management, L.P. and affiliated entities have reported beneficial ownership of 5.8% of Editas Medicine, Inc. common stock.

TCG Crossover Fund III, L.P., along with its general partner and an individual, has reported beneficial ownership of 9.9% of Editas Medicine's common stock, including exercisable warrants.

Commodore Capital LP and its principals have reported a 9.9% beneficial ownership stake in Editas Medicine, Inc. following recent warrant acquisitions.

The Vanguard Group reported 0% beneficial ownership in Editas Medicine Inc. following an internal realignment, with subsidiaries now reporting separately.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 7.9% beneficial ownership stake in Editas Medicine, Inc. as of March 31, 2025.

Deep Track Capital, LP and its affiliates have reported a complete divestment of their beneficial ownership in Editas Medicine, Inc., holding 0% of the common stock as of December 31, 2024.